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Rates of infection with antibiotic-resistant bacteria have increased precipitously over the
past several decades, with far-reaching healthcare and societal costs. Recent evidence
has established a link between antibiotic resistance genes in human pathogens and
those found in non-pathogenic, commensal, and environmental organisms, prompting
deeper investigation of natural and human-associated reservoirs of antibiotic resistance.
Functional metagenomic selections, in which shotgun-cloned DNA fragments are selected
for their ability to confer survival to an indicator host, have been increasingly applied
to the characterization of many antibiotic resistance reservoirs. These experiments have
demonstrated that antibiotic resistance genes are highly diverse and widely distributed,
many times bearing little to no similarity to known sequences. Through unbiased
selections for survival to antibiotic exposure, functional metagenomics can improve
annotations by reducing the discovery of false-positive resistance and by allowing for the
identification of previously unrecognizable resistance genes. In this review, we summarize
the novel resistance functions uncovered using functional metagenomic investigations
of natural and human-impacted resistance reservoirs. Examples of novel antibiotic
resistance genes include those highly divergent from known sequences, those for which
sequence is entirely unable to predict resistance function, bifunctional resistance genes,
and those with unconventional, atypical resistance mechanisms. Overcoming antibiotic
resistance in the clinic will require a better understanding of existing resistance reservoirs
and the dissemination networks that govern horizontal gene exchange, informing best
practices to limit the spread of resistance-conferring genes to human pathogens.
Keywords: functional metagenomics, antibiotic resistance, bifunctional resistance gene, environmental resistance,
resistance reservoir, transferable resistance

OVERVIEW
It is estimated that infection with antibiotic-resistant pathogens
incurs over $25 billion in societal and healthcare costs annually in the United States (CDC, 2011). More than 70% of
hospital-acquired bacterial infections are currently resistant to
at least one of the major antibiotics used as standard treatment (Stone, 2009), and patient deaths as a result of hospitalacquired infections have increased by over 675% during the
past 20 years (NIAID, 2012). As the incidence and spectrum
of antibiotic resistance increases (Arias and Murray, 2009),
antibiotic development has slowed to a trickle (Spellberg et al.,
2008), further hindering the effectiveness of antibiotics to treat
infectious disease. The majority of acquired antibiotic resistance genes in bacterial pathogens are obtained via horizontal gene transfer (HGT) (Ochman et al., 2000), likely with
environmental origins (Benveniste and Davies, 1973; Wright,
2010; D’Costa et al., 2011). Accordingly, an increasing impetus has been placed on cataloging antibiotic resistance reservoirs
(Allen et al., 2009b, 2010), determining how resistance genes
are most readily transferred to the clinic (Marshall and Levy,
2011; Smillie et al., 2011), and identifying resistance mechanisms
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heretofore unseen in clinical settings (Jeon et al., 2011; Tao et al.,
2012).

TRADITIONAL MECHANISMS OF ANTIBIOTIC RESISTANCE
An antibiotic-resistant phenotype can be either an acquired trait
or intrinsic to the bacterium in question. In the case of intrinsic
resistance, antibiotic therapy is rendered ineffective due to a preexisting physiological trait of the species, such as reduced accessibility to or absence of a drug target (Alekshun and Levy, 2007;
Martinez, 2008; Davies and Davies, 2010; Dantas and Sommer,
2012). Examples of intrinsic antibiotic resistance include vancomycin tolerance in Gram-negative bacteria (the outer cell
membrane reduces access to the peptidoglycan target) (Arthur
and Courvalin, 1993) and biofilm formation in numerous organisms (perhaps providing resistance via reduced drug penetration and/or altered microenvironments) (Stewart and Costerton,
2001). Conversely, acquired antibiotic resistance stems from the
expression of a specific resistance gene and is commonly the result
of de novo mutation or the acquisition of resistance-conferring
genes on mobile genetic elements (e.g., plasmids, transposons,
integrons) (Walsh, 2003). The antibiotic resistance genes present
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in a microbial community that are capable of transfer to a new
host are collectively referred to as the “transferable resistome.”
Intrinsic resistance is, by definition, limited to the context of
the parent organism, whereas acquired resistance represents a
more flexible phenotype, and its prevalence is more immediately responsive to selection pressure (Martinez, 2008). As nearly
all infectious bacteria were antibiotic-susceptible prior to the
introduction of antibiotic therapy (Houndt and Ochman, 2000;
Davies and Davies, 2010), the exceeding majority of resistance in
human pathogens is acquired, either through mutation or HGT
(Alekshun and Levy, 2007). This resistance represents a diversity
of biochemical mechanisms that break down into three general
categories (Walsh, 2000, 2003): (1) inactivation of the antibiotic,
(2) reducing intracellular antibiotic concentration through efflux
or permeability barriers, and (3) altering the cellular target of the
antibiotic, reducing their association.
Perhaps the most intuitive of resistance mechanisms, antibiotic inactivation, is sub-categorized into two groups: enzymes
that inactivate drugs via degradation (e.g., the β-lactamases) vs.
those that function via chemical modification. The β-lactamases
are characterized by their ability to cleave the four-membered
ring present in all β-lactam antibiotics and are some of the
best-studied and widely-distributed antibiotic resistance genes
(for review, see Jacoby and Munoz-Price, 2005). These enzymes
confer high-level antibiotic resistance and are found associated with mobile DNA elements and integrated into bacterial chromosomes. β-lactamases function via either a serine
active site or metal cation cofactor (Jacoby and Munoz-Price,
2005) and can be found across bacterial phyla. Antibioticmodifying enzymes are also phylogenetically widespread, as well
as mechanistically diverse. These enzymes can confer tolerance
toward numerous drugs, including the aminoglycoside (Davies
and Wright, 1997), tetracycline (Yang et al., 2004), amphenicol
(Schwarz et al., 2004), and macrolide-lincosamide-streptogramin
(Weisblum, 1998) antibiotics, typically functioning via covalent
modification of the drug with some functional moiety (e.g.,
acetyl, phosphoryl, nucleotidyl, glycosyl, and hydroxyl groups)
(Alekshun and Levy, 2007).
The intracellular concentration of any given antibiotic can be
reduced by either efflux mechanisms to remove the drug from the
cytosol or permeability barriers that limit the drug’s uptake. Many
antibiotics have poor activity against Gram-negative pathogens
due to efflux systems (Levy, 1992), most notably the RND superfamily transporters (Li and Nikaido, 2004, 2009). Other major
families of efflux systems include the MFS, SMR, and ABC superfamily transporters, which are present in both Gram-negative and
-positive organisms (Li and Nikaido, 2004, 2009). Although commonly chromosomal, many efflux systems are found on plasmids
and other mobile elements and can confer drug-specific, classspecific, or multidrug resistance (Poole, 2005). Some permeability
barriers, such as the Gram-negative outer membrane (Arthur and
Courvalin, 1993), represent intrinsic antibiotic resistance, while
in other instances, permeability barriers are acquired. Examples
include multidrug-resistance via the altered expression of Gramnegative porin proteins (e.g., OmpF in Escherichia coli and OprD
in Pseudomonas) (Delcour, 2009) and glycopeptide resistance due
to thickened Gram-positive cell walls (Cui et al., 2006).

Antibiotic resistance via cellular target modification often
occurs via chromosomal mutation and represents a common means by which the fluoroquinolone, sulfonamide, and
trimethroprim antibiotics, among others, are tolerated (Alekshun
and Levy, 2007). In the case of the fluoroquinolones, mutations to a variety of residues within the quinolone-resistancedetermining-region (QRDR) of the DNA gyrase GyrA or topoisomerase IV ParC/GrlA prevent the interaction of the synthetic
antibiotic with its target, facilitating resistance (Hooper, 1999).
Importantly, resistance to fluoroquinolones via mutation is typically recessive, suppressing the acquisition of a resistant phenotype in the presence of wild-type GyrA or ParC/GrlA and
thus preventing widespread horizontal dissemination of resistant gene variants (Wolfson and Hooper, 1989; Soussy et al.,
1993). However, a plasmid-borne GyrA protection protein, Qnr,
has been discovered that confers low-level fluoroquinolone resistance (Tran and Jacoby, 2002) and can potentiate the incidence
of QRDR mutations, which combined provide high levels of
resistance (Jacoby, 2005). Both the sulfonamides and trimethroprim competitively inhibit enzymes within the folate biosynthesis pathway: mutations to the dihydropteroate synthase and
dihydrofolate reductase (DHFR) enzymes can reduce affinity
for sulfonamides and trimethroprim, respectively, and provide
tolerance to the antibiotics (Huovinen et al., 1995). In addition to arising de novo, both sulfonamide- and trimethroprimresistant enzymes are present on mobile DNA elements, providing resistance to numerous bacteria via HGT (Alekshun and Levy,
2007). Other highly mobile mechanisms of target-modification
include vancomycin resistance via the modification of peptidoglycan precursors (Bugg et al., 1991), aminoglycoside resistance
via methylation of the 16S rRNA subunit (Galimand et al.,
2003), and macrolide resistance from 23S rRNA methylases
(Zhanel et al., 2001).
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RESERVOIRS OF TRANSFERABLE ANTIBIOTIC RESISTANCE
Research on antibiotic resistance over the past 70 years has
focused on traditionally pathogenic bacteria isolated in a clinical
setting and the role of antibiotic resistance genes already present
in those species (Sommer et al., 2009; Davies and Davies, 2010).
The resistance phenotype, however, is an ancient function of environmental bacteria (D’Costa et al., 2011), despite being largely
absent from human pathogens prior to the antibiotic age (Hughes
and Datta, 1983; Houndt and Ochman, 2000), with estimates
that β-lactamases have existed for over 2 billion years (Hall and
Barlow, 2004; Hall et al., 2004). Moreover, diverse mechanisms
of antibiotic resistance have been discovered in nearly all environments (D’Costa et al., 2006; Allen et al., 2010; Davies and
Davies, 2010; Wright, 2010); seemingly each new metagenomic
study uncovers numerous examples of resistance genes previously
unreported in public databases (Allen et al., 2009b; Sommer et al.,
2009; Donato et al., 2010; Forsberg et al., 2012). In short, the
diversity and abundance of antibiotic resistance in commensal
microbiota and environmental settings dwarfs that which is seen
in the context of human pathogens.
Importantly, environmental antibiotic resistance is not only
widespread, but also represents the likely origins of the resistance
seen in human pathogens. It has been known for 40 years that
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environmental bacteria share the same resistance mechanisms
as those seen in pathogens (Benveniste and Davies, 1973), with
documented examples of environmental resistance genes moving from natural settings into human pathogens (Poirel et al.,
2002, 2005). It is becoming increasingly evident that human
pathogens and environmental organisms share antibiotic resistance genes; a recent study described seven resistance genes
from non-pathogenic soil organisms, conferring tolerance to five
antibiotic classes, with perfect identity to genes from phylogenetically and geographically diverse pathogens (Forsberg et al.,
2012). Given the staggering diversity of environmental resistance,
high adaptability of bacteria, and strong selection pressure for
antibiotic resistance, the question of antibiotic resistance is “not a
matter of if but only a matter of when” (Walsh, 2000).
To understand when novel resistance will appear in human
pathogens and perhaps diminish its impact, one must understand how new resistance genes are most frequently acquired by
pathogenic bacteria. Since the answer is, most commonly, via
HGT (Hughes and Datta, 1983; Ochman et al., 2000; Alekshun
and Levy, 2007), understanding the complement of resistance
genes most likely to be transferred to pathogens is crucial to
predicting resistance acquisition. Although cataloging the repertoire of resistance genes on Earth remains a prohibitively large
undertaking, techniques for interrogating the resistance properties of complex microbial communities exist and are being applied
toward the identification of diverse and novel resistance from
numerous settings. Importantly, these studies are focused not
only on environmental locales, but also on the resistomes associated with human and animal microbiota (Shoemaker et al., 2001;
Sommer et al., 2010b; Sommer and Dantas, 2011). Although
antibiotic resistance may have its origins in the environment
(Benveniste and Davies, 1973; Wright, 2010; D’Costa et al., 2011),
the commensal resistome shares many resistance genes with both
pathogens (Sommer et al., 2010b) and environmental organisms (Forsberg et al., 2012) and represents a likely route through
which these populations exchange resistance genes (Smillie et al.,
2011; Sommer and Dantas, 2011). Focused efforts to understand
how pathogens acquire antibiotic resistance will require a greater
appreciation for the diversity of resistance genes and in which
environments and under what conditions these resistance genes
are most accessible to human pathogens.

Functional metagenomics uncovers novel resistance

quantify resistance genes of known sequence, circumventing the
need for culture (Knapp et al., 2010), but are only able to detect
previously described genes and often require expression cloning
and subsequent experimentation to verify function. In addition,
annotation of antibiotic resistance genes in shotgun-sequenced
microbial communities has proven challenging, as homologybased functional gene comparisons often fail due to low sequence
similarity to previously discovered resistance genes, and in silico
analyses are unable to confirm resistance function.
In contrast with standard techniques, functional metagenomics
is a culture- and sequence-independent means of identifying
transferrable antibiotic resistance in complex metagenomes. This
method (Figure 1) involves shotgun-cloning total community
DNA into an expression vector and transforming the library into
an indicator host (commonly the model organism E. coli). The
resulting transformants are then selected for the desired function
(e.g., antibiotic resistance), and metagenomic DNA fragments are
sequenced and annotated to identify causal survival-conferring
genes (Allen et al., 2009b; Sommer et al., 2009). Functional
metagenomics offers three classical advantages for the unbiased
interrogation of complex resistomes (Daniel, 2005; Sommer and
Dantas, 2011): (1) no need to culture organisms, (2) no required
knowledge of resistance gene sequence, and (3) direct association
between a genotype and a demonstrated resistance phenotype.
Additionally, functional metagenomic selections specifically identify those genes within a metagenome capable of conferring
antibiotic tolerance to the indicator host when expressed exogenously (i.e., they distinguish transferrable resistance from intrinsic resistance) (Dantas and Sommer, 2012). Recent improvements
to the throughput of functional metagenomics (Forsberg et al.,
2012) unlock the potential for the experiments of scale needed
identify the specific sequences, and environments, most readily able to confer resistance to human pathogens, frequently
represented by the opportunistic pathogen E. coli.

NOVEL RESISTANCE MECHANISMS UNCOVERED BY
FUNCTIONAL METAGENOMIC SELECTIONS
The following sections review novel resistance mechanisms and
genes uncovered by functional metagenomic selections; these
studies are summarized in Table 1.
GENES HIGHLY DIVERGENT FROM KNOWN RESISTANCE GENES

INTERROGATING ANTIBIOTIC RESISTANCE PROPERTIES IN
COMPLEX MICROBIAL COMMUNITIES
Traditionally, either culture-based (D’Costa et al., 2006) or PCRbased approaches (Perez-Perez and Hanson, 2002) have been used
to study antibiotic resistance properties from microbial communities. While both techniques have led to major discoveries
(Galan et al., 2013), both have inherent limitations that have contributed to an under-sampling of resistance genes from diverse
microbial habitats. The majority of bacteria remain recalcitrant
to culturing (Daniel, 2005) and are therefore not interrogated
when culture-dependent techniques are employed. Additionally,
linking a resistance phenotype to a causal genotype is a timeconsuming process, often necessitating experimental scope to
be limited to a small number of organisms, rather than whole
communities. PCR screens are an effective means to identify or
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PCR-based screens for known resistance genes are able to detect
novel variants with minor sequence differences, but due to the
requirement for conserved primer binding sites, they are often
unable to detect genes that have diverged significantly from
the canonical example. In comparison, functional metagenomic
selections for antibiotic resistance frequently identify genes that
are less than 65% identical at the amino acid level to known resistance genes. In this way, functional metagenomics expands our
knowledge of what sequence variants are tolerated in a resistance
gene while preserving the resistance mechanism, as well as what
mutations lead to expanded specificity profiles.
β-lactamases are one of the largest and best studied classes
of resistance determinants, and yet, novel β-lactamases are regularly uncovered with sequence-independent techniques (Allen
et al., 2009b; Sommer et al., 2009; Donato et al., 2010; Cheng
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FIGURE 1 | Overview of functional metagenomic selections. Total
metagenomic DNA is extracted from a microbial community sample,
sheared, and ligated into an expression vector (Step 1) and is
subsequently transformed into a suitable library host (Step 2) to create a
metagenomic library. The library is then plated on media containing
antibiotics inhibitory to the wild-type host (Step 3) to select for

et al., 2012; Forsberg et al., 2012). In the first functional metagenomic selection for antibiotic resistance in the human gut microbiome, Sommer et al. identified ten novel β-lactamase families
whose eleven members were only 35–61% identical to known
genes (Sommer et al., 2009). Based on phylogenetic analysis
with PhyloPythia, (McHardy et al., 2007) these genes originated
primarily from the Firmicutes and Bacteroidetes phyla, which
comprise the majority of the human gut microbiota but have been
undersampled because they are less readily culturable in aerobic environments than Proteobacteria. Functional selection for
β-lactam resistance in metagenomic libraries constructed from
remote Alaskan soil revealed 13 novel β-lactamases of all four
Ambler classes that were ≤67% identical to any known, functionally characterized gene (Allen et al., 2009b). In the case of the class
B β-lactamases, several genes appear to be more closely related to
the ancestral gene of that class than to clinically isolated genes,
providing context for the evolution of clinical isolates. The study
also confirmed that overall sequence similarity does not necessarily confer similar drug susceptibility profiles, supporting discovery techniques that confirm the function of identified genes.
Functional metagenomic selections also enable the detection
of highly diverse classes of resistance genes, defined by substrate specificity more than shared sequence identity. For instance,
aminoglycoside 6 -N-acetyltransferases [AAC(6 )s] are difficult
to identify via PCR because of their high sequence diversity
(Riesenfeld et al., 2004). Sommer et al. identified six AAC(6 )s
with less than 48% amino acid identity to known genes and a
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metagenomic fragments conferring antibiotic resistance. Metagenomic
fragments present in colonies growing on antibiotic selection media are
then PCR-amplified (Step 4) and sequenced using either traditional Sanger
sequencing or next-generation sequencing methods (Step 5). Finally, reads
are assembled and annotated in order to identify the causative antibiotic
resistance genes (Step 6).

methyltransferase conferring resistance to sisomycin with only
26.3% shared identity. Riesenfeld et al. and other studies have
identified many aminoglycoside resistance genes less than 70%
identical to previously reported sequences (Riesenfeld et al., 2004;
Donato et al., 2010; Torres-Cortes et al., 2011; Cheng et al.,
2012; McGarvey et al., 2012). Similarly, two novel bleomycin
resistance genes were isolated from an activated sludge metagenomic library (Mori et al., 2008). Bleomycin resistance proteins
act primarily by sequestering the antibiotic through electrostatic interactions, so their sequences tolerate an extreme amount
of divergence while still maintaining the resistance function.
Nevertheless, the study confirmed that all known bleomycin resistance proteins contain a proline near the N-terminus and have an
acidic pI of <5, improving computational annotation of this class.
Finally, McGarvey et al. identified an ADP-ribosyltransferase that
was much longer any previously characterized using functional
metagenomic selections (McGarvey et al., 2012). This full-length
gene may not have been identified by PCR-based screens, but
its discovery, enabled by functional metagenomics, expands our
knowledge of the sequence diversity tolerated within this resistance class.
RESISTANCE GENES THAT WOULD NOT HAVE BEEN PREDICTED
BY SEQUENCE

A major limitation of sequence-based metagenomics is its restriction to antibiotic resistance genes that are recognizable as
members of a previously characterized class. BLAST, the most
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Table 1 | Functional metagenomic investigations of antibiotic resistance reservoirs.
Resistance reservoir

Date

Novel resistance function identified

FUNCTIONAL METAGENOMIC INVESTIGATIONS OF ENVIRONMENTAL RESERVOIRS
Soil (remnant oak savannah)
2004
First use of functional metagenomic selections to
investigate environmental antibiotic resistance;
Nine novel aminoglycoside-resistance genes

Total DNA queried*

References

5.4 GB

Riesenfeld et al., 2004

Activated sludge

2008

Two novel bleomycin-resistance genes

3.2 GB

Mori et al., 2008

Remote Alaskan soil

2009

13 novel β-lactamases; First discovery of
bifunctional β-lactamase

12.4 GB

Allen et al., 2009b

Gypsy moth larvae midgut
isolates

2009

ramA (AraC transcriptional regulator)

0.3 GB

Allen et al., 2009a

Remote Alaskan soil

2010

pexA (novel chloramphenicol transporter)

13.2 GB

Lang et al., 2010

Activated sludge

2010

Six novel chloramphenicol-modifying resistance
genes; Novel aminoglycoside-resistance gene

1.9 GB

Parsley et al., 2010

Soil (apple orchard)

2010

Nine novel β-lactamases; Three novel
aminoglycoside-resistance genes; A novel
tetracycline efflux pump

13.4 GB

Donato et al., 2010

Alluvial soil

2011

Est136, chloramphenicol acetate esterase

1.6 GB

Tao, 2011; Tao et al., 2012

Soil (agricultural, nature
reserve)

2011

Tm8-3 (novel dihydrofolate reductase)

3.6 GB

Torres-Cortes et al., 2011

Wetland soil

2011

EstU1, family VIII carboxylesterase

0.3 GB

Kim et al., 2008; Jeon et al., 2011

Gull gut microbiome

2011

31 β-lactam resistance genes of undetermined
mechanism

20.5 GB

Martiny et al., 2011

Urban soil

2012

Novel MFS and ABC transporters; Five novel
aminoglycoside-resistance genes;
ADP-ribosyltransferase longer than any previously
discovered

2.8 GB

McGarvey et al., 2012

Multidrug-resistant soil
2012
Novel β-lactamases; D-cycloserine efflux pump
2.6 GB
isolates
FUNCTIONAL METAGENOMIC INVESTIGATIONS OF HUMAN-ASSOCIATED RESERVOIRS
Human oral microbiome
2003
Tetracycline-inactivating protein tet(37)
0.4–1.4 MB

Forsberg et al., 2012

Human oral microbiome

2006

Tetracycline-resistance genes of undetermined
mechanism

27.8 MB

Diaz-Torres et al., 2006

Human gut and oral
microbiome

2009

10 new β-lactamase classes; Seven novel
aminoglycoside-resistance genes

9.3 GB

Sommer et al., 2009

Pig gut microbiome

2009

Tetracycline-resistance genes galE1 and galE2 of
undetermined mechanism

0.1 GB

Kazimierczak et al., 2009

Human gut microbiome

2012

Confirmed bifunctional aminoglycoside-resistance
gene; Novel β-lactamase; Novel
aminoglycoside-resistance gene

12.5 GB

Cheng et al., 2012

Diaz-Torres et al., 2003

*For comparison, the genome size of E. coli K-12 substrain MG1655 is 4.64 MB.

commonly used annotation tool, requires a threshold of shared
sequence identity for a gene to be considered a member of an
established gene class. Therefore, by definition, this method limits the ability to identify novel resistance genes. In addition, while
profile hidden Markov model (HMM)-based annotation provides
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a sensitive, statistically sound analysis method capable of identifying remote homologs, these models still rely on underlying multiple sequences alignments of previously characterized proteins. In
addition, current profile HMM databases provide high-level classification of antibiotic resistance genes (e.g., “Beta-Lactamase,”
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rather than “TEM Beta-Lactamase”), providing little functional
information about the gene and its potential resistance profile.
Therefore, while these techniques have the potential to identify
genes that have low sequence identity to known resistance genes,
in the absence of additional functional confirmation, they cannot identify novel resistance mechanisms or verify that sequence
variants are functional.
Functional metagenomics identifies resistance-conferring elements without prior knowledge of the sequence, circumventing
this limitation. For instance, in a selection for tetracycline resistance encoded by the human oral metagenome, Diaz-Torres
et al. discovered a novel tetracycline resistance gene, tet(37)
(Diaz-Torres et al., 2003). In vitro analysis indicated that tet(37)
inactivates tetracycline, making it one of only three tetracycline
resistance proteins to utilize this mechanism (Thaker et al., 2010).
tet(37) resembles flavoproteins, oxidoreductases, and NAD(P)requiring enzymes in sequence and conserved motifs, but has no
identity to tet(X), the first tetracycline-inactivating gene identified. It is therefore unlikely that computational annotation would
have identified it as a resistance gene (Diaz-Torres et al., 2003).
Similarly, a study of soil microbiota identified a dihydrofolatereducing gene, Tm8-3, that resembles 3-oxoacyl-(acyl-carrierprotein) reductases but not dhfr, the target of trimethoprim
(Torres-Cortes et al., 2011). A screen of an activated sludge
metagenome also identified six resistance genes that appear
to inactivate chloramphenicol through enzymatic modification,
but which share no significant identity with known chloramphenicol acetyltransferases (Parsley et al., 2010). Although these
genes may become important for clinical resistance in the
future, their existence would likely have been overlooked without
high-throughput functional selections independent of previous
sequence knowledge.
Drug efflux is a widespread resistance mechanism common
to many antibiotic classes, but individual transporters identified
through computational annotation methods cannot be assigned
antibiotic efflux properties without functional validation. Small
changes in protein structure can change the drug specificity
profile of an efflux pump and confer or eliminate resistance.
Therefore, functional metagenomic selections are an attractive
alternative for high-throughput characterization of transporters
with tentative resistance annotations (Torres-Cortes et al., 2011).
For instance, in their study of soil isolate metagenomes, Forsberg
et al. identified a novel gene with only low identity to a
drug/metabolite transporter. Were it not for functional selection
of D-cycloserine resistance, this putative transporter would never
have been identified as an antibiotic resistance gene (Forsberg
et al., 2012). McGarvey et al. identified five novel MFS transporters and two ABC transporters from an urban soil that conferred resistance to tetracycline, chloramphenicol, or trimethoprim (McGarvey et al., 2012). Lang et al. successfully identified
pexA, a novel amphenicol MFS transporter, despite its low identity (33%) to other drug resistance transporters, including any
known chloramphenicol exporters (Lang et al., 2010).
BIFUNCTIONAL ENZYMES

Broad-spectrum resistance as a result of bifunctional resistance
genes, the fusion of two complementary enzymatic functions into
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a single gene, is recognized as an increasing occurrence in many
pathogens (Kim et al., 2006; Perez et al., 2007; Chandrakanth
et al., 2008). Functional metagenomics provides an opportunity to identify fusion genes that are functionally active against
multiple classes of antibiotic agents from natural resistance reservoirs and commensal organisms, and which have the potential to
appear in clinically relevant bacteria.
Recently, functional metagenomic selections of a remote
Alaskan soil revealed a novel bifunctional β-lactamase (Allen
et al., 2009b). The 609-amino-acid protein is nearly double
the length of a typical β-lactamase and is a natural fusion of
genes for two different β-lactamase subclasses. The C-terminal
domain (356 residues) aligns with class C β-lactamases, while
the N-terminal domain (253 residues) aligns with class D
β-lactamases, each contributing to the resistance profile of the
full-length gene. The class C homologue confers resistance to
cephalexin, while the class D homologue is responsible for resistance to amoxicillin, ampicillin, and carbenicillin. The bifunctional fusion gene therefore expands the resistance profile of the
full-length gene beyond what either domain is responsible for
alone (Allen et al., 2009b).
While this was the first bifunctional β-lactamase to be discovered, bifunctional resistance has been documented in the
past, particularly against the aminoglycoside antibiotics (Daigle
et al., 1999; Centrón and Roy, 2002; Dubois et al., 2002;
Mendes et al., 2004; Robicsek et al., 2006). The most common
mechanism of aminoglycoside resistance is deactivation of the
molecule through modification by cytoplasmic enzymes: aminoglycoside acetyltransferases (AACs), aminoglycoside phosphotransferases (APHs), or aminoglycoside nucleotidyltransferases
(ANTs). Four bifunctional enzymes, combining two complementary aminoglycoside-modifying enzymes as separate domains
into a single open reading frame, significantly broadening the
resistance profile, are known. Ferretti et al. reported the first
bifunctional enzyme, AAC(6 )/APH(2 ), demonstrating that it is
capable of both acetylation (ACC activity found in N-terminal
domain) and phosphorylation (APH activity found in C-terminal
domain) of aminoglycosides (Ferretti et al., 1986). This bifunctional enzyme was also discovered in a functional metagenomics
study of the human gut microbiota (Cheng et al., 2012). The
ability to doubly modify aminoglycosides enables this enzyme
to confer resistance to nearly all clinically relevant aminoglycosides except streptomycin and spectinomycin (Daigle et al., 1999).
Similarly, the bifunctional resistance enzymes characterized as
an AAC(3)-Ib/AAC(6 )-Ib (Dubois et al., 2002), an ANT(3 )Ii/AAC(6 )-IId (Centrón and Roy, 2002), and an AAC(6 )30/AAC(6 )-Ib (Mendes et al., 2004) all exhibit an expanded
resistance profile by combining two different aminoglycosidemodifying enzymes into a single gene.
AAC(6 )-Ib-cr is the only bifunctional resistance enzyme identified capable of conferring resistance to two different structural classes of antibiotics, aminoglycosides and fluoroquinolones
(Vetting et al., 2008). A variant of a common aminoglycoside
acetyltransferase AAC(6 )-Ib, AAC(6 )-Ib-cr is also capable of
N-acetylation of fluoroquinolones. Only two codon changes in
the original enzyme are responsible for the fluoroquinoloneresistance phenotype (Vetting et al., 2008).
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The merger of two genes with complementary enzymatic
activities represents a novel mechanism for overcoming the
increasing challenge by antibiotics, resulting in extremely broad
resistance to entire antibiotic structural classes. It is likely that
more examples of bifunctional resistance exist in the environment, and functional metagenomics provides a powerful
technique for the discovery of functionally active bifunctional
enzymes that may have great clinical implications.
UNUSUAL MECHANISMS OF RESISTANCE

Functional metagenomic selections have the potential to identify
another important class of resistance genes, those that have a primary role in the cell other than antibiotic resistance. This includes
housekeeping genes whose overexpression provides resistance,
general stress response transcription factors, and enzymes with
promiscuous activity.
Selections for trimethoprim resistance, for example, frequently
identify genes encoding DHFR, the cellular target of trimethoprim (Torres-Cortes et al., 2011; McGarvey et al., 2012). Cloning
a dhfr homolog into a high copy-number plasmid results in overexpression of DHFR, which sequesters the antibiotic (Flensburg
and Skold, 1987). McGarvey et al. identified 19 highly divergent DHFRs from a soil metagenome. The proteins shared only
7–44% amino acid identity in pairwise alignments, but a subset selected for further investigation conferred similar levels
of trimethoprim resistance on the host when cloned into the
same position of a high-copy number vector (McGarvey et al.,
2012). Although clinical isolates of E. coli that massively overproduce DHFR as a result of promoter mutations and intrinsically resistant dhfr homologs have been identified (Flensburg
and Skold, 1987), in most instances, resistance conferred by
overexpression of a heterologous gene is likely independent of
its ability to replace the host homolog. Rather, the introduced
gene may sequester enough of the antibiotic to allow the native
homolog to continue functioning. Selections for D-cycloserine
resistance that identify D-alanine-D-alanine ligase, the target of
the antibiotic, likely fall under the same class (Cheng et al., 2012).
Creating and screening libraries in low-copy number vectors
is essential in these instances to identify genes that are naturally resistant to the antibiotic, rather than simply selecting for
overexpression.
In contrast, antibiotic resistance conferred by transcriptional
regulators represents the successful interaction of a heterologous
gene with existing host cellular pathways. The AraC transcriptional stress response regulators marA, soxS, and rob share a highly
overlapping regulon and mediate low-level antibiotic resistance in
E. coli and its close relative E. fergusonii (Alekshun and Levy, 1997;
Martin and Rosner, 2002). As might be expected, these genes
are often identified in functional metagenomic selections against
chloramphenicol, tetracyclines, and other antibiotics when E. coli
is the indicator host. A homolog of the AraC transcriptional regulator ramA, from Enterobacter sp., was also identified from a
gypsy moth larvae gut isolate metagenomic library as conferring
resistance to E. coli against multiple antibiotics of different classes
when overexpressed (Allen et al., 2009a). These results provide
valuable information about the ability of horizontally acquired
genes from closely related phyla to incorporate into a cell at the
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regulatory level, a mechanism of antibiotic resistance that has
been previously under-considered.
Certain genes identified by functional metagenomic selections
are surprising in that they more closely resemble protein families
that perform unrelated functions in the cell than previously identified resistance genes. They may represent instances of expanded
substrate specificity, where mutation to a gene with an unrelated
function confers resistance. By first screening a soil metagenomic
library for esterase activity, Jeon et al. identified a family VIII
carboxylesterase that hydrolyzes both esters and the amide bond
of β-lactams, apparently utilizing the same catalytic site residues
for both reactions (Jeon et al., 2011). The protein changes that
enable it to also hydrolyze β-lactams are currently unidentified. A
novel chloramphenicol acetate esterase, EstDL136, isolated from a
soil metagenome, hydrolyzes the amide linkage of both chloramphenicol and its synthetic derivative florfenicol (Tao, 2011; Tao
et al., 2012). Many of the surrounding genes in the metagenomic
fragment are most closely related to Sphingomonadaceae, which
are frequently considered for bioremediation for their ability to
degrade many compounds (Stolz, 2009). EstDL136 may have
originally evolved to detoxify another compound, later expanding
its substrate specificity to chloramphenicol.

FUTURE DIRECTIONS AND CHALLENGES
Functional metagenomic selections have proven to be an excellent technique for the discovery of novel antibiotic resistance
mechanisms and genes encoded by varied environmental and
human-associated microbial communities. As library sizes continue to increase, diverse indicator hosts are established, and
techniques for improved functional selection and mechanistic
determination are developed, functional metagenomics will only
become better powered to explore the transferable resistome of
complex microbial communities.
All of the metagenomic libraries discussed above were constructed in E. coli. The commercial availability of competent E. coli with extremely high transformation efficiencies has
made this organism the preferred host for library construction, and these studies show that E. coli permits the heterologous expression of genes from many phyla. However, there
are many clinically important classes of antibiotics that are
intrinsically inactive against this Gram-negative species (e.g., glycopeptides, macrolides, oxazolidinones), prohibiting functional
metagenomic selections in this host from identifying antibiotic
resistance genes active against these classes. Development of a
Gram-positive indicator host will represent a major step forward
for the field (Riesenfeld et al., 2004; Sommer et al., 2009). This
host must also exhibit a high transformation efficiency to enable
the creation of metagenomic libraries large enough to permit the
discovery of novel resistance genes and should lack restrictionmodification systems or other host defenses that would prevent
the expression of foreign DNA. E. coli mutants that mimic Grampositive species through the alteration of cell membrane and wall
structure are another possible alternative (Tamae et al., 2008).
The taxa from which antibiotic resistance genes can be
expressed in E. coli are also limited by the ability of the host
to recognize gene promoters and ribosome binding sites and
translate them into functional proteins. Engineering E. coli to
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produce tRNA that recognize rare codons and alternative sigma
factors will expand the range of taxa interrogated (Riesenfeld
et al., 2004; Sommer et al., 2009, 2010a).
Finally, genes of unknown function should be further investigated to determine their mechanisms of resistance. Functional
metagenomic selections that uncover a multitude of confirmed
resistance genes in a high-throughput manner often require complementary biochemical experimentation to understand novel
mechanisms of antibiotic resistance. Many metagenomic functional selections have identified resistance-conferring inserts
whose mechanisms remain obscure because they cannot be determined based on sequence alone (Riesenfeld et al., 2004; DiazTorres et al., 2006; Kazimierczak et al., 2009; Martiny et al., 2011;
McGarvey et al., 2012). These genes are excellent candidates for
future functional characterization.

ALTERNATIVE STRATEGIES TO COMBAT ANTIBIOTIC
RESISTANCE
The depth and diversity of antibiotic resistance genes uncovered
by functional metagenomic selections, many of which are associated with mobile genetic elements, brings to light the need
for novel strategies to combat antibiotic-resistant pathogens.
Alternative approaches that modulate the host immune response
(e.g., immunomodulatory peptides, vaccination, therapeutic
antibodies) or target the pathogen (e.g., anti-virulence initiatives,
phage therapy, antibiotic potentiators) have been explored with
some success (Planson et al., 2011; Pieren and Tigges, 2012).
For instance, recent studies have suggested engineered bacteriophage as an adjuvant to enhance the bactericidal activity of
antibiotics and avoid evolution of resistance to either (Lu and
Collins, 2009; Parracho et al., 2012). In this case, bacteriophage
is engineered to repress non-essential genes (e.g., the SOS system)
not directly targeted by antibiotics, weakening the cell and potentiating antibiotic activity. Other adjuvant compounds that inhibit
intrinsic repair pathways or cell tolerance mechanisms are being
explored (Fischbach, 2011).
Several permeabilizing products capable of disturbing the cell
membrane have been identified, thus allowing antibiotics to penetrate the cells more efficiently. One such product is the low
molecular-weight oligosaccharide nanomedicine OligoG, which
is able to disturb multidrug-resistant bacteria (Khan et al., 2012).
Drug efflux pumps, both specific and multidrug-resistant,
may be inhibited through a variety of strategies. These include
interfering with the expression of a functional transporter at
different stages between transcription and final assembly, interfering with the assembly of channel proteins, designing inhibitors
that compete with the antibiotic for efflux, disrupting the energy
source, and blocking the efflux channel (Pages and Amaral, 2009).
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